Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

NCT04633967 is registered in ClinicalTrials.gov with Maritime Neurology as lead sponsor.

NCT NCT04633967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04633967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.
Lead sponsor
Maritime Neurology
Phase
Observational
Overall status
Completed
Start date
May 15, 2016
Completion date
February 28, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

frequency of infusion reactions in novel versus standard protocol in multiple sclerosis